je.st
news
Home
› OPKO Submits Investigational New Drug Application To Initiate A Phase 2a Trial For Its Long-Acting Coagulation Factor VIIa-CTP To Treat Hemophilia
OPKO Submits Investigational New Drug Application To Initiate A Phase 2a Trial For Its Long-Acting Coagulation Factor VIIa-CTP To Treat Hemophilia
2015-02-04 06:38:34| drugdiscoveryonline Home Page
OPKO Health, Inc. announced the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to conduct a Phase 2a study of OPKO's long-acting version of coagulation Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
Tags: to
application
trial
factor
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||